Neurocrine Biosciences delivered a better-than-expected second quarter, with revenues and adjusted earnings per share topping the Zacks Consensus Estimate, and raised its 2026 Ingrezza sales outlook. Second-quarter revenues increased 39% year over year to $959 million, above the consensus estimate of $901.5 million, while adjusted earnings of $2.85 per share rose 73% and beat the consensus estimate of $2.26. Ingrezza sales reached $716 million versus the $628.6 million consensus mark, Crenessity generated $184 million compared with the $170.8 million estimate, and Vykat XR added $54 million from May 18 through quarter-end. Management raised 2026 Ingrezza net product sales guidance to $2.825-$2.875 billion from $2.7-$2.8 billion, implying roughly 13% growth at the midpoint. The company also raised 2026 adjusted research and development guidance to $1.14-$1.19 billion and selling, general and administrative guidance to $1.325-$1.35 billion.
Neurocrine Biosciences IncBeats Q2 estimates and raises Ingrezza guidance
Bristol-Myers Squibb Company
Teva Pharma Industries Ltd ADR